Peer-reviewed industrial hemp research papers, sorted by publication date. Browse the latest findings on hemp cultivation, processing, materials science, biomedical applications, and regulatory science from PubMed, OpenAlex, and other indexed sources.
Objetivo. Caracterizar a utilização dos canabinoides na terapêutica de doenças neurológicas e sistêmicas, sob justificativa do advento de novas tecnologias, conhecimentos e potenciais usos das drogas pertencentes a esse grupo como um modulador da dor, inflamação e crises convulsivas. Método. Revisão narrativa de literatura conduzida entre 20 de maio de 2021 e 09 de junho de 2021 nas bases de dados PubMED, SciElo, Medline, Cochrane e Scopus utilizando os descritores: “Cannabidiol” AND “Pharmacolo
Epilepsy is an abnormal neurologic disorder distinguished by the recurrent manifestation of seizures, and the precise underlying mechanisms for its development and progression remain uncertain. In recent years, the hypothesis that inflammatory mediators and corresponding pathways contribute to seizures has been supported by experimental results. The potential involvement of neuroinflammation in the development of epilepsy has garnered growing interest. This review centers attention on the involv
Aim: Acute cannabis intoxication can impair motor skills and cognitive functions. Given possible impairment related to acute cannabis intoxication, we explored whether mobile phone-based sensors (e.g., GPS, text/phone logs) can detect episodes of acute cannabis intoxication (subjective “high” state) as self-reported in natural environments by young adults. Methods: Young adults (ages 18-25), who reported cannabis use at least twice per week, were recruited by research registry and Craigslist to
Our findings highlight the significance of de novo pathogenic SYNGAP1 variants at the intron 16/exon 17 junction in the SYNGAP1-related neurodevelopmental disorders, providing novel insights into the genetic basis and diagnosis of these disabilities.
The authors share the cautionary tale of a case of MG in a pediatric patient who was treated with RNS for intractable epilepsy associated with LGS. Although slurred speech, fatigue, muscle weakness, and other symptoms might stem from increased seizure activity and/or medication side effects, they could also be due to MG development.
Resumen. El síndrome de Dravet es una encefalopatía epiléptica severa de muy poca incidencia (1 por cada 20.00040.000), es catalogada como rara y de poco conocimiento y sospecha médica, por tal razón dificulta su diagnóstico. Se trata de una alteración en el gen SCN1A, principal codificador de la subunidad alfa 1 del canal de sodio.
 Presentación del caso: Paciente femenino de 6 meses de vida, nacimiento por cesárea, embarazo de curso normal, sin complicaciones, madre con antecedente de un
Fenfluramine (Fintepla<sup>®</sup>) is approved for the treatment of seizures associated with the rare epileptic encephalopathies Dravet syndrome and Lennox-Gastaut syndrome. Fenfluramine is extensively metabolized; thus, patients with hepatic impairment (HI) might experience changes in exposure to fenfluramine or its metabolites. In this phase 1 study, we investigated the pharmacokinetics (PK) and safety of a single oral dose of 0.35 mg/kg fenfluramine in subjects with mild (n = 8), moderate (n
Introdução. O potencial terapêutico dos compostos presentes na Cannabis sp. apresenta relevância clínica em diversas doenças neurológicas. O uso de canabidiol (CBD) é uma das opções no tratamento da epilepsia. O extrato com teor elevado de CBD possui resultados de redução da frequência, severidade e intensidade das convulsões, especialmente em crianças. Objetivo. Por meio de uma revisão narrativa da literatura, buscou-se observar as diferenças entre os efeitos do extrato de Cannabis sp full spec
Lifestyle interventions are strategies used to self-manage medical conditions, such as epilepsy, and often complement traditional pharmacologic and surgical therapies. The need for integrating evidence-based lifestyle interventions into mainstream medicine for the treatment of epilepsy is evident given that despite the availability of a multitude of treatments with medications and surgical techniques, a significant proportion of patients have refractory seizures, and even those who are seizure-f
The majority of patients with cannabis use disorder (CUD) regularly take medication. Cannabinoids influence metabolism of some commonly prescribed drugs. However, little is known about the characteristics and frequency of potential cannabis-drug (CDIs) and drug-drug interactions (DDIs) in patients with CUD. Therefore, our study aimed to determine the prevalence and characteristics of drug interactions in patients with CUD during inpatient treatment on an addiction-specific ward over a six-year-p
Peer-reviewed industrial hemp research by Sigrid C. Disse; Hanna Küpper; A. Böck; Georg-Christoph Korenke; Georgia Ramantani; Birgit Weidner; Martin Preisel; Regina Trollmann; Adelheid Wiemer‐Kruel; Knut Brockmann published in European Journal of Paediatric Neurology (2025).
At 12 mg/kg/day and an ICER threshold of £20,000-£30,000, we provide evidence for the cost effectiveness of add-on cannabidiol treatment for patients with TSC-associated seizures aged ≥ 2 years who are refractory to current treatment.
Idiopathic (genetic) epilepsy is a common neurologic disorder of dogs and 25%-30% of these dogs are refractory to antiseizure drug therapy. The purpose of this open-label clinical trial was to evaluate the potential efficacy and tolerability of a traditional Chinese herbal formula Di Tan Tang as an add-on therapy for dogs with refractory presumptive idiopathic epilepsy. Eight dogs with refractory presumptive idiopathic epilepsy were evaluated for seizure frequency 3 months prior to and 3 months
This pre-specified treatment protocol is safe and efficacious in controlling ARSs in cases with established epilepsy who are not critically sick. External validation from other parts of the world/centers and a more diverse epilepsy population are required before generalizing the protocol into clinical practice.
The materials of this document analysis were patient and public submissions to a government enquiry into barriers to a health technology. By providing submissions, both patients and the public were actively engaging in the development of health policy.
Use of a CPA to conduct CMM in CYSHCN-CMC decreased medication burden, resolved, and prevented adverse events, reduced health care-related costs, reduced hospital readmissions and was well-accepted and implemented collaboratively with pLTCF providers.
Over-the-counter cannabidiol (CBD) products are showing substantial growth in marked share in recent years. However, the knowledge about health effects of these products is currently weak. In an explorative, retrospective online survey, the reasons for consumption, possible health-promoting or therapeutic effects, and adverse effects among CBD consumers in Germany were investigated. The anonymous questionnaire was accessible from 21 February 2023 to 20 June 2023. Participants (n = 208) were recr
ABSTRACT Fibromyalgia is an increasingly prevalent condition resulting in high morbidity and economic burden for sufferers. Minimal to modest benefit has been achieved by pharmacotherapies, creating a strong rationale for novel therapies. Substantial evidence has implicated the endocannabinoid system in the modulation of fibromyalgia symptoms. However, the therapeutic potential and potential adverse effects of cannabis-based therapy in fibromyalgia are still under-reported, leading to clinicians
The core subunits of the K<sub>V</sub>7.2, K<sub>V</sub>7.3, and K<sub>V</sub>7.5 channels, encoded by the <i>KCNQ2</i>, <i>KCNQ3</i>, and <i>KCNQ5</i> genes, are expressed across various cell types and play a key role in generating the M-type K<sup>+</sup> current (<i>I</i><sub>K(M)</sub>). This current is characterized by an activation threshold at low voltages and displays slow activation and deactivation kinetics. Variations in the amplitude and gating kinetics of <i>I</i><sub>K(M)</sub> can
Cannabidiol (CBD), a non-psychoactive compound derived from the cannabis plant, has been extensively studied for its potential therapeutic effects on various central nervous system (CNS) disorders, including epilepsy, chronic pain, Parkinson's disease, and stress-related neuropsychiatric disorders. However, the pharmacological mechanisms of CBD have not been fully elucidated due to the complexity of their targets. In this study, we reported that the transient receptor potential canonical 4 (TRPC
Epilepsy, a prevalent neurological disorder affecting millions globally, manifests as recurrent synchronous neuronal discharges that disrupt normal cerebral function. Emerging evidence characterizes this condition as a network-level hyperexcitability disorder driven by aberrant neuroelectrical synchronization. At the molecular level, intracellular calcium (Ca<sup>2+</sup>) overload is increasingly recognized as a key contributor to seizure initiation and propagation. The regulation of neuronal C
Pharmacists in Norway have a satisfactory level of knowledge and confidence in counselling regarding main issues of epilepsy and treatment with ASMs, but some knowledge gaps were identified. More educational opportunities to close these gaps may facilitate the pharmacist's role in building health literacy for this patient group and improve drug safety.
Spinal cord injury (SCI) is a pathological neurological condition that leads to significant motor dysfunction. It is a condition that occurs as a result of tragic accidents, violent acts, or as a consequence of chronic diseases or degenerative changes. The current treatments for patients with SCI have moderate efficacy. They improve the quality of life of patients, but they are still doomed to long-term disability. In response to the modern directions of research on possible therapeutic methods
Rett syndrome (RTT) is a rare X-linked neurodevelopmental disorder characterized by an early phase of apparently normal development, followed by rapid regression in language, motor coordination, and purposeful hand use. We report the case of a female pediatric patient with classic RTT confirmed by a de novo pathogenic mutation in the MECP2 gene. The patient developed typically until 18 months of age, when she began to lose speech, motor function, social interaction, and developed stereotypic han